(MedPage Today) — Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the CALLIPER trial suggested.
On…
Source link : https://www.medpagetoday.com/meetingcoverage/ectrims/117645
Author :
Publish date : 2025-09-25 20:18:00
Copyright for syndicated content belongs to the linked Source.
